Physician profile
Timothy Edison
NPI 1861425902
$7,260.97
in general payments reported to CMS, 2019-2025
29 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $325 · 2021: $1,132 · 2022: $1,623 · 2023: $1,743 · 2024: $859 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,523.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,539.09 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $910.25 | 2020-2025 | Stelara, Tremfya, Simponi |
| Boston Scientific Corporation | $643.00 | 2021-2024 | Exalt Model D |
| Endogastric Solutions, INC | $499.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $427.47 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $322.98 | 2022-2023 | Ibsrela |
| Celgene Corporation | $305.37 | 2021-2024 | Zeposia |
| Olympus Corporation of The Americas | $209.70 | 2019 | |
| Genzyme Corporation | $207.79 | 2022-2025 | |
| Madrigal Pharmaceuticals | $203.83 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $181.06 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $142.18 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.26 | 2021-2023 | Trulance |
| Lumendi LLC | $75.67 | 2021 | |
| Ironwood Pharmaceuticals, INC | $70.69 | 2021-2023 | Linzess |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $70.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $59.93 | 2024-2025 | Dupixent |
| Amgen INC. | $42.67 | 2023 | Avsola, Amjevita |
| Ethicon US, LLC | $40.24 | 2021-2022 | |
| Mauna Kea Technologies, INC. | $37.19 | 2020-2023 | |
| Vivus LLC | $25.60 | 2021 | |
| Kls-Martin L.P. | $24.99 | 2023 | |
| Alnylam Pharmaceuticals INC. | $24.58 | 2021 | |
| Conmed Corporation | $24.50 | 2023 | Conmed Biliary, Conmed Hemostasis |
| Redhill Biopharma INC. | $19.54 | 2021 | |
| Medtronic, INC. | $16.75 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.18 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.72 | 2021 | |
| Laborie Medical Technologies Corp. | $14.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Edison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.